C D Herling
Overview
Explore the profile of C D Herling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling C, et al.
Blood
. 2022 Jun;
140(20):2113-2126.
PMID: 35704690
The BCL2 inhibitor venetoclax has been approved to treat different hematological malignancies. Because there is no common genetic alteration causing resistance to venetoclax in chronic lymphocytic leukemia (CLL) and B-cell...
2.
Schrader A, Crispatzu G, Oberbeck S, Mayer P, Putzer S, von Jan J, et al.
Nat Commun
. 2018 Feb;
9(1):697.
PMID: 29449575
T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy. Here we integrated large-scale profiling data of alterations in gene expression, allelic copy number (CN), and nucleotide sequences...
3.
Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider J, Babu V, et al.
Leukemia
. 2016 Oct;
31(5):1177-1186.
PMID: 27773933
Treatment resistance becomes a challenge at some point in the course of most patients with chronic lymphocytic leukemia (CLL). This applies to fludarabine-based regimens, and is also an increasing concern...